Walmart has settled the U.S. government's lawsuit accusing its pharmacies of unlawfully dispensing opioids and other controlled substances across the country, the Department of Justice announced. The agreement closes out a civil case the federal government first brought against the retail giant alleging its pharmacies fueled the nationwide opioid epidemic, though the financial and injunctive terms of the deal were not immediately available.
According to WKZO, the Justice Department said it reached a settlement with Walmart resolving allegations that its pharmacies failed to comply with obligations under the Controlled Substances Act when filling opioid prescriptions. The lawsuit had accused Walmart of fueling the opioid crisis by unlawfully dispensing prescriptions from its pharmacies, per the government's own allegations in the case. The report, credited to Thomson Reuters reporters Andrew Goudsward in Washington, D.C., and Jonathan Stempel in New York, noted that settlement terms were not immediately disclosed.
A Six-Year Legal Fight Dating Back to 2020
The case traces back to December 2020, when the DOJ filed its original civil lawsuit against Walmart in Delaware federal court, alleging the retailer racked up hundreds of thousands of Controlled Substances Act violations across its network of more than 5,000 in-store pharmacies dating as far back as June 2013, according to Courthouse News Service. The complaint accused Walmart of filling invalid prescriptions issued by so-called pill-mill prescribers and failing to detect or report suspicious orders. Under 21 U.S.C. § 842 of the Controlled Substances Act, pharmacies and distributors can face civil monetary penalties per violation for failing to maintain effective controls against drug diversion, a framework that once put Walmart's potential exposure in the billions of dollars, per the same account.
Before the DOJ's civil suit, federal prosecutors in the Eastern District of Texas had already spent 2016 to 2018 investigating Walmart's opioid dispensing practices, conducting raids and issuing subpoenas before ultimately declining criminal prosecution, according to Justia Law. Walmart also tried to get ahead of the government's case, filing its own preemptive lawsuit against the DOJ and DEA in October 2020 seeking a court ruling on pharmacists' legal obligations under the Controlled Substances Act. A federal judge dismissed that Walmart suit in February 2021 on sovereign immunity grounds, according to FindLaw. In that filing, Walmart had argued individual pharmacists, not corporate policy, bore responsibility for deciding whether to refill prescriptions.
A Judge Narrowed the Case in 2024
The lawsuit's scope shifted in March 2024, when U.S. District Judge Colm Connolly narrowed the DOJ's case by dismissing allegations tied to suspicious order reporting to the DEA, according to Quartz. Connolly's ruling did allow claims to proceed that focused on whether corporate compliance staff and individual pharmacists knowingly dispensed improper controlled substances, eliminating the narrower claim that pharmacists simply failed to document red flags while preserving the broader knowledge-based allegations, the outlet reported.
Distinct From Walmart's Earlier Opioid Settlements
This federal settlement is separate from Walmart's earlier reckonings over opioids. In November 2022, Walmart agreed to a $3.1 billion nationwide settlement framework to resolve thousands of lawsuits brought by state, local, and tribal governments, with all 50 states finalizing participation by December 2022, according to Walmart's own announcement. That deal mandated court-ordered pharmacy oversight improvements but included no admission of corporate liability. Separately, in October 2024, Walmart agreed to pay $123 million to settle a shareholder class-action lawsuit alleging company executives misled investors by failing to disclose ongoing federal investigations into its opioid dispensing practices between 2017 and 2020, Courthouse News Service reported, with the shareholder claims tied to stock declines after news of the federal probes became public.
The DOJ's pursuit of Walmart is part of a broader federal push against national retail pharmacy chains. A separate settlement required Walgreens to pay up to $350 million to resolve federal allegations of illegally filling invalid controlled-substance prescriptions, according to WMBD, and Walgreens, CVS, and Walmart had previously agreed to pay a combined total of more than $13 billion in nationwide state and local settlements.
Pharmacy Chains Have Also Won in Court
Not every opioid-related case has gone against the big chains. In May, a Florida circuit judge ruled in favor of Walmart, CVS, and Walgreens, rejecting a public-nuisance and racketeering lawsuit brought by 16 hospital systems that had sought more than $2 billion for opioid-related medical treatment costs, as Hoodline previously reported. The hospital systems had alleged that pharmacy dispensing practices directly inflated emergency and inpatient healthcare expenses.
Overdose Deaths Have Fallen for Three Straight Years
The settlement lands against a backdrop of improving national overdose numbers. Provisional data from the Centers for Disease Control and Prevention shows U.S. drug overdose deaths dropped to roughly 69,973 in 2025, a third consecutive annual decline after fatalities peaked at more than 110,000 in 2022. CDC records show opioid overdoses have accounted for more than 905,000 deaths in the U.S. between 1999 and 2025.
For now, the biggest open question is what Walmart will actually pay and what compliance obligations it will face going forward, since the DOJ's Thursday announcement did not immediately disclose financial or injunctive terms. That leaves the final numbers on one of the federal government's most prominent opioid-related civil enforcement actions still unresolved for the public record.
